Rockefeller Capital Management
HEPA

Rockefeller Capital Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Rockefeller Capital Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$1K – 3953
2021
Q4 		$1K Hold
1
– – ﹤0.01% 3646
2021
Q3 		$1K Hold
1
– – ﹤0.01% 3572
2021
Q2 		$1K Sell
1
-19
-95% -$34.8K ﹤0.01% 3334
2021
Q1 		$36K Buy
+20
New +$43.8K ﹤0.01% 2027

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.22B AUM 16.98% 1-Year Est. Return

Rockefeller Capital Management's HEPA Position: Q1 2022 in Review

Rockefeller Capital Management sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 1 share — an estimated $1K sold.

Rockefeller Capital Management first reported a position in HEPA in Q1 2021 and held it in 4 quarters. The position peaked at $36K in Q1 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

  • Rockefeller Capital Management reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 1 Hepion Pharmaceuticals share in Q1 2022, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Hepion Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Rockefeller Capital Management's Hepion Pharmaceuticals position peaked at $36K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on Rockefeller Capital Management's 13F filing for Q1 2022, filed 13 May 2022.